Mutual of America Capital Management LLC Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual of America Capital Management LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 4.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 180,357 shares of the biopharmaceutical company’s stock after selling 8,546 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $14,611,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Altshuler Shaham Ltd grew its holdings in Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 121 shares during the period. Nilsine Partners LLC lifted its position in shares of Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. lifted its position in shares of Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. lifted its position in shares of Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares in the last quarter. Finally, Revolve Wealth Partners LLC lifted its position in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the transaction, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. Insiders have sold 9,000 shares of company stock worth $721,180 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $68.65 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a one year low of $68.06 and a one year high of $87.86. The firm has a market capitalization of $85.47 billion, a PE ratio of 15.26, a P/E/G ratio of 0.89 and a beta of 0.19. The firm has a 50-day moving average of $72.97 and a two-hundred day moving average of $76.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. During the same period in the prior year, the company posted $1.67 earnings per share. Gilead Sciences’s quarterly revenue was down 3.7% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 6.85 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Royal Bank of Canada cut their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Finally, Mizuho reduced their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $85.36.

Read Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.